LH · Labcorp Holdings Inc. · Financials
$312.15
-2.05 (-0.65%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$25.32B
Shares
81.10M
Volume · Oct 9
607.87K
Avg daily vol (3M)
740.51K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$13.95B
+7.2%
FY2025
Net Income
$876.5M
+17.5%
FY2025
Gross Margin
28.76%
+0.9pp
FY2025
Operating Margin
9.92%
+1.6pp
FY2025
Diluted EPS
$10.46
+18.3%
FY2025
Operating Cash Flow
$1.64B
+3.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $14.71B – $14.83B | $14.35B | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B | $11.55B | $11.33B | $10.31B | $9.55B | $8.68B | $6.01B | $5.81B | $5.67B | $5.54B | $5B | $4.69B | $4.51B | $4.07B | |
| — | $10.2B | $9.94B | $9.38B | $8.8B | $8.16B | $8.14B | $9.03B | $8.3B | $8.16B | $7.22B | $6.7B | $5.78B | $3.81B | $3.59B | $3.42B | $3.27B | $2.91B | $2.72B | $2.63B | $2.38B | |
| — | $4.14B | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B | $3.25B | $3.18B | $3.09B | $2.85B | $2.9B | $2.2B | $2.22B | $2.25B | $2.27B | $2.1B | $1.97B | $1.87B | $1.69B | |
| — | — | 28.76% | 27.86% | 27.67% | 31.26% | 38.01% | 35.43% | 28.15% | 28.03% | 29.99% | 29.88% | 33.45% | 36.65% | 38.28% | 39.67% | 41.04% | 41.92% | 41.98% | 41.59% | 41.57% | |
| — | $2.22B | $2.22B | $2.23B | $2.02B | $1.76B | $1.69B | $1.73B | $1.62B | $1.57B | $1.5B | $1.35B | $1.63B | $1.2B | $1.13B | $1.11B | $1.16B | $1.03B | $958.9M | $935.1M | $808.7M | |
| — | $295.8M | $280M | $256.4M | $219.8M | $193.6M | $229.5M | $275.4M | $243.2M | $231.7M | $216.5M | $179.5M | $164.5M | $76.7M | $81.7M | $86.3M | $85.8M | $72.7M | $62.6M | $57.9M | $54.9M | |
| — | $696.3M | $681.1M | $643.5M | $577.3M | $537.2M | $577M | $624.7M | $577.2M | $552.1M | $533.2M | $499.2M | $457.8M | $245.5M | $230.1M | $229.8M | $231.4M | $203.6M | $195.1M | $179.7M | $162.8M | |
| — | — | — | — | $55.7M | $55.9M | $44.3M | $33M | $33.1M | $52.1M | $76M | $64.7M | $113.9M | $18.9M | $24.9M | — | — | — | $13.5M | $37.9M | $50.6M | |
| — | $1.5B | $1.38B | $1.09B | $725.6M | $1.44B | $3.05B | $2.45B | $1.33B | $1.33B | $1.31B | $1.27B | $996.8M | $910.4M | $990.9M | $1.02B | $948.4M | $978.8M | $935.9M | $842.9M | $777M | |
| — | — | 9.92% | 8.35% | 5.97% | 12.11% | 23.21% | 17.49% | 11.51% | 11.7% | 12.66% | 13.3% | 11.48% | 15.14% | 17.06% | 18.05% | 17.11% | 19.56% | 19.94% | 18.71% | 19.1% | |
| — | $2.19B | $2.07B | $1.73B | $1.3B | $1.97B | $3.63B | $3.07B | $1.91B | $1.88B | $1.84B | $1.77B | $1.45B | $1.16B | $1.22B | $1.25B | $1.18B | $1.18B | $1.13B | $1.02B | $939.8M | |
| — | $227.2M | $224.1M | $208.3M | $199.6M | $179.8M | $211.8M | $207.4M | $240.7M | $244.2M | $235.1M | $219.1M | $274.9M | $109.5M | $96.5M | $94.5M | $87.5M | $70M | $62.9M | -$72M | -$56.6M | |
| — | -$37.9M | -$55M | $60.2M | $15.5M | -$32.2M | $15.5M | -$226.3M | -$225.3M | -$57.4M | -$227.7M | -$197M | -$270.8M | -$83.7M | -$75.3M | -$79.3M | -$82.3M | -$4.9M | -$3.8M | -$2.1M | -$1.4M | |
| — | -$22.6M | -$13.3M | -$1.4M | -$1.4M | $5.4M | $26.5M | $2.9M | $9.8M | $11.6M | $11.3M | $7.9M | $10M | $14.3M | $16.9M | $21.4M | $9.5M | $10.6M | $13.8M | $14.4M | $77.9M | |
| — | $230.2M | $229.8M | $212.4M | $188.5M | $233.9M | $690M | $662.1M | $280M | $384.4M | -$155.4M | $360.7M | $287.3M | $314.1M | $340.2M | $359.4M | $333M | $344M | $329M | $307.9M | $325.5M | |
| — | $1B | $876.5M | $746M | $418M | $1.28B | $2.38B | $1.56B | $823.8M | $883.7M | $1.23B | $711.8M | $437.6M | $511.2M | $573.8M | $583.1M | $519.7M | $558.2M | $543.3M | $464.5M | $476.8M | |
| — | — | 6.28% | 5.73% | 3.44% | 10.78% | 18.1% | 11.13% | 7.13% | 7.8% | 11.9% | 7.45% | 5.04% | 8.5% | 9.88% | 10.28% | 9.38% | 11.16% | 11.57% | 10.31% | 11.72% | |
| — | $1.2M | $1.2M | $1.1M | $1.2M | $1.5M | $2.2M | $900K | $1.1M | $200K | $5.8M | $1.1M | $1.1M | $1.4M | $1.6M | $1.7M | $13.4M | $13.4M | $12.3M | $13.3M | $0 | |
| — | $935M | $1.11B | $543.7M | $613.9M | $977.8M | $2.35B | $1.77B | $914.5M | $754.3M | $1.48B | $416.9M | $161.1M | $434.5M | $570.6M | $607M | $476.7M | $585.2M | $621.5M | $327.8M | $538.1M | |
| USD/shares | — | $12.18 | $10.54 | $8.89 | $4.80 | $14.05 | $24.60 | $13.74 | $7.23 | $7.48 | $10.30 | $5.96 | $3.81 | $5.18 | $5.46 | $5.23 | $4.47 | $4.66 | $4.35 | $3.63 | $3.51 |
| USD/shares | $18.10 – $18.55* | $12.09 | $10.46 | $8.84G | $4.77G | $13.97G | $24.39G | $13.64 | $7.17 | $7.40 | $10.15 | $5.86 | $3.74 | $5.08 | $5.37 | $5.15 | $4.39 | $4.54 | $4.28 | $3.57 | $3.38 |
| shares | — | — | 83.2M | 83.9M | 87.1M | 91.1M | 96.7M | 113.26M | 113.96M | 118.03M | 119.19M | 119.31M | 115M | 98.71M | 104.99M | 111.39M | 116.4M | 119.89M | 125.01M | 127.69M | — |
| shares | — | — | 83.8M | 84.4M | 87.6M | 91.6M | 97.5M | 114.07M | 114.77M | 119.43M | 120.94M | 121.41M | 117.1M | 100.57M | 106.86M | 113.37M | 118.5M | 122.69M | 126.99M | 130.14M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.41B in buybacks, $933M in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-06-30 | USD 4,700,000 | 10-Q filed 2026-08-05 |
| Current operating lease liabilities | 2026-06-30 | USD 180,300,000 | 10-Q filed 2026-08-05 |
| Current portion of long-term debt | 2026-06-30 | USD 900,000 | 10-Q filed 2026-08-05 |
| Current portion of notes payable | 2026-06-30 | USD 900,000 | 10-Q filed 2026-08-05 |
| Noncurrent finance lease liabilities | 2026-06-30 | USD 61,600,000 | 10-Q filed 2026-08-05 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 5,857,600,000 | 10-Q filed 2026-08-05 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 661,000,000 | 10-Q filed 2026-08-05 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.16×
Peer median 6.93×
EV/EBIT
20.74×
Peer median 34.53×
P/E (TTM)
25.82×
Peer median 35.17×
Peer medians compare against the 23 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $10,876,500,000 | $10,144,300,000 | $9,415,100,000 | $9,203,500,000 | $10,363,600,000 | $9,253,400,000 | $7,000,100,000 | — |
| Biopharma Laboratory Services | $3,098,200,000 | $2,922,600,000 | $2,774,200,000 | $2,697,300,000 | $2,860,700,000 | $4,877,700,000 | $4,578,100,000 | — |
| Covance Drug Development | — | — | — | — | — | — | — | $4,313,100,000 |
| LabCorp Diagnostics | — | — | — | — | — | — | — | $7,030,800,000 |
By Geography (USD)
| Component | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| North America | $13,093,700,000 | $11,525,300,000 | — |
| Europe | $2,050,800,000 | $1,512,200,000 | — |
| Other Countries | $976,400,000 | $941,000,000 | $1,199,700,000 |
| Canada | — | — | $333,300,000 |
| Switzerland | — | — | $532,900,000 |
| United Kingdom | — | — | $507,900,000 |
| United States | — | — | $8,981,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics | $1,779,900,000 | $1,606,300,000 | $1,591,300,000 | $2,025,500,000 | $3,205,600,000 | $2,801,300,000 | $1,086,000,000 | $1,166,700,000 |
| Biopharma Laboratory Services | $498,500,000 | $458,900,000 | $396,300,000 | $389,100,000 | $501,000,000 | $721,600,000 | $411,500,000 | $303,600,000 |
| Corporate | -$482,200,000 | -$670,800,000 | -$644,100,000 | -$468,800,000 | -$404,500,000 | -$299,400,000 | -$167,300,000 | -$144,600,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diagnostics | 16.4% | 15.8% | 16.9% | 22% | 30.9% | 30.3% | 15.5% |
| Biopharma Laboratory Services | 16.1% | 15.7% | 14.3% | 14.4% | 17.5% | 14.8% | 9% |
Key facts
CIK
920148
CUSIP
504922105
13F (30d)
51 filings
41 filers
Visit website
Investor relations